Emulate Inc.

Emulate Inc., doing business as Emulate, a Boston-based biotechnology company specializing in organ-on-chip microphysiological systems, operates as a prime contractor supplying hardware, reagent kits, maintenance services, and research platforms to federal health and defense agencies. The company competes predominantly in full-and-open procurements without set-aside designations, though roughly 35% of recent awards carry Total Small Business set-asides. Emulate qualifies as a small business and is a for-profit corporation; the source does not identify additional SBA designations or minority ownership.

Emulate's core capability is manufacturing and servicing human organ-on-chip systems — microphysiological platforms that replicate human organ functions in vitro to support drug development, regulatory science, and alternatives to animal testing. The company's product line includes modular hardware (Zoe Culture Modules in various configurations, Orb Hub Modules), specialized chip kits (Chip-S1 Stretchable, Chip-R1 Rigid, Liver-Chip Quad-Culture, Brain Organoid systems), reagent kits, and extended warranty and maintenance service agreements. Recent representative contracts include a $354 thousand sole-source FDA procurement in January 2022 for a Liver Human Emulation System; a $218.1 thousand FDA Total Small Business set-aside in June 2022 for two Zoe Culture Module 2 units and two Orb Hub Modules; a $217.7 thousand NIAID Total Small Business set-aside in August 2024 for upgrades to existing Zoe Culture Module systems; and a $248 thousand FDA purchase order in September 2025 for Chip-S1 Basic Research Kits. The company also holds a cooperative agreement with the FDA's Center for Drug Evaluation and Research (awarded September 2024, completion August 2026) focused on validating the Liver-Chip for predicting drug-induced liver injury in preclinical drug development.

Customer concentration sits heavily with the Department of Health and Human Services. The FDA accounts for 13 awards and $1.9 million in combined potential value, followed by NIAID (5 awards, $822 thousand), the National Cancer Institute (5 awards, $403 thousand), the National Center for Advancing Translational Sciences (4 awards, $361 thousand), and the National Institute of Environmental Health Sciences (4 awards, $259 thousand). These five customer entities represent 31 of 46 awards and $3.8 million combined potential value (79% coverage). The Department of the Army Research Development and Engineering Command places three awards worth $371 thousand. The remaining 15 awards scatter across 12 additional federal agencies, including the Department of Veterans Affairs, the National Institute on Drug Abuse, and the National Institute of Allergy and Infectious Diseases. Activity peaked in 2023 with 12 awards, declined to 8 in 2024, and has slowed to 3 in 2025 and 1 in 2026 year-to-date. Six awards (combined potential value $683 thousand) face ultimate completion within the next twenty-four months and will recompete.

Emulate operates exclusively as a prime contractor; the source identifies no subcontracting footprint. The company's award portfolio spans nearly two decades (first award June 2015) but the recent five-year activity shows growth from 2022 to 2023 followed by contraction. Combined potential value across all 46 awards is $4.9 million, though combined dollars obligated across all awards reaches $9.7 million (197% of potential value), indicating that many purchase orders have been modified upward or extended. Analytically, 19 awards fall under PSC Laboratory Equipment and Supplies; 14 awards map to NAICS Analytical Laboratory Instrument Manufacturing; 6 awards fall under equipment maintenance and repair. The source does not identify Emulate as holding seats on government-wide vehicles, IDIQs, or BPAs; awards are issued as direct purchase orders by individual federal agencies.